Therapeutic angiogenesis for treating cardiovascular diseases

Theranostics

Volumn 2, Issue 8, 2012, Pages 801-814

  Deveza, Lorenzo ^a,b   Choi, Jeffrey ^c   Yang, Fan ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Angiogenesis; Cardiovascular diseases

Indexed keywords

BIOLOGICAL FACTOR; BIOMATERIAL; GROWTH FACTOR; POLYMER;

ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL BASED GENE THERAPY; CELL HOMING; CELL SURVIVAL; CELLS; CONTROLLED RELEASE FORMULATION; COVALENT BOND; DNA MODIFICATION; DRUG RELEASE; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HYDROGEL; STEM CELL GENE THERAPY; THERAPEUTIC ANGIOGENESIS;

EID: 84866035310     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4419     Document Type: Article

References (63)

1. Roger V.L, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation, 2012. 125(1): e2-e220.
2. Libby P and Theroux P. Pathophysiology of coronary artery disease. Circulation, 2005. 111(25): 3481-8.
3. Jawad E and Arora R. Chronic stable angina pectoris. Dis Mon, 2008. 54(9): 671-89.
4. McFalls E.O, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med, 2004. 351(27): 2795-804.
5. Carmeliet P and Jain R.K. Molecular mechanisms and clinical applica-tions of angiogenesis. Nature, 2011. 473(7347): 298-307.
6. Xu K and Cleaver O. Tubulogenesis during blood vessel formation. Semin Cell Dev Biol, 2011. 22(9): 993-1004.
7. Heil M, et al. Arteriogenesis versus angiogenesis: similarities and dif-ferences. J Cell Mol Med, 2006. 10(1): 45-55.
8. Takahashi T, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med, 1999. 5(4): 434-8.
9. Horvath K.A. Transmyocardial laser revascularization. J Card Surg, 2008. 23(3): 266-76.
10. Losordo D.W and Dimmeler S. Therapeutic angiogenesis and vasculo-genesis for ischemic disease. Part I: angiogenic cytokines. Circulation, 2004. 109(21): 2487-91.
11. Richardson T.P, et al. Polymeric system for dual growth factor delivery. Nat Biotechnol, 2001. 19(11): 1029-34.
12. Leeper N.J, Hunter A.L, and Cooke J.P. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation, 2010. 122(5): 517-26.
13. Rafii S and Lyden D. Therapeutic stem and progenitor cell transplanta-tion for organ vascularization and regeneration. Nat Med, 2003. 9(6): 702-12.
14. Asahara T, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J, 1999. 18(14): 3964-72.
15. Fadini G.P, Agostini C, and Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis, 2010. 209(1): 10-7.
16. Cleland J.L, et al. Development of poly-(D,L-lactide--coglycolide) mi-crosphere formulations containing recombinant human vascular endo-thelial growth factor to promote local angiogenesis. J Control Release, 2001. 72(1-3): 13-24.
17. Formiga F.R, et al. Sustained release of VEGF through PLGA micropar-ticles improves vasculogenesis and tissue remodeling in an acute myo-cardial ischemia-reperfusion model. J Control Release, 2010. 147(1): 30-7.
18. Golub J.S, et al. Sustained VEGF delivery via PLGA nanoparticles pro-motes vascular growth. Am J Physiol Heart Circ Physiol, 2010. 298(6): H1959-65.
19. Lin C.C and Anseth K.S. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm Res, 2009. 26(3): 631-43.
20. Zisch A.H, et al. Cell-demanded release of from synthetic VEGF, bioin-teractive cell ingrowth matrices for vascularized tissue growth. FASEB J, 2003. 17(15): 2260-2.
21. Huang X and Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release, 2001. 73(2-3): 121-36.
22. Lee J and Lee K.Y. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm Res, 2009. 26(7): 1739-44.
23. Jeon O, et al. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nano-spheres and fibrin gel. Biomaterials, 2006. 27(8): 1598-607.
24. Kim M.S, et al. Development of functional fibrous matrices for the con-trolled release of basic fibroblast growth factor to improve therapeutic angiogenesis. Tissue Eng Part A, 2010. 16(10): 2999-3010.
25. Pike D.B, et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels con-taining VEGF and bFGF. Biomaterials, 2006. 27(30): 5242-51.
26. Ruvinov E, Leor J, and Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials, 2010. 31(16): 4573-82.
27. Fujita M, et al. Therapeutic angiogenesis induced by controlled release of fibroblast growth factor-2 from injectable chitosan/non-anticoagulant heparin hydrogel in a rat hindlimb ischemia model. Wound Repair Re-gen, 2007. 15(1): 58-65.
28. DuBose J.W, Cutshall C, and Metters A.T. Controlled release of tethered molecules via engineered hydrogel degradation: model development and validation. J Biomed Mater Res A, 2005. 74(1): 104-16.
29. Ehrbar M, et al. Cell-demanded liberation of VEGF121 from fibrin im-plants induces local and controlled blood vessel growth. Circ Res, 2004. 94(8): 1124-32.
30. Sun Q, et al. Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis. Pharm Res, 2010. 27(2): 264-71.
31. Layman H, et al. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomater, 2009. 5(1): 230-9.
32. Patil S.D, Papadmitrakopoulos F, and Burgess D.J. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and an-giogenesis. J Control Release, 2007. 117(1): 68-79.
33. Peattie R.A, et al. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials, 2006. 27(9): 1868-75.
34. Tengood J.E, et al. Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. Biomaterials, 2010. 31(30): 7805-12.
35. Sun G, et al. Functional neovascularization of biodegradable dextran hydrogels with multiple angiogenic growth factors. Biomaterials, 2011. 32(1): 95-106.
36. Silva E.A and Mooney D.J. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials, 2010. 31(6): 1235-41.
37. Tang D.W, et al. Heparinized chitosan/poly(gamma-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin. Biomaterials, 2010. 31(35): 9320-32.
38. Garbern J.C, et al. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials, 2011. 32(9): 2407-16.
39. Yu J, et al. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials, 2009. 30(5): 751-6.
40. Chen S.Y, et al. Autologous transplantation of EPCs encoding FGF1 gene promotes neovascularization in a porcine model of chronic myocardial ischemia. Int J Cardiol, 2009. 135(2): 223-32.
41. Duan H.F, et al. Treatment of myocardial ischemia with bone mar-row-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther, 2003. 8(3): 467-74.
42. Iwaguro H, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation, 2002. 105(6): 732-8.
43. Matsumoto R, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myo-cardial infarction. Arterioscler Thromb Vasc Biol, 2005. 25(6): 1168-73.
44. Sun L, et al. Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Bio-chem Biophys Res Commun, 2007. 357(3): 779-84.
45. Cheng Z, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac perfor-mance. Mol Ther, 2008. 16(3): 571-9.
46. Jabbarzadeh E, et al. Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell trans-plantation approach. Proc Natl Acad Sci U S A, 2008. 105(32): 11099-104.
47. Tang J, et al. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg, 2009. 36(4): 644-50.
48. Tang J, et al. Combination of chemokine and angiogenic factor genes and mesenchymal stem cells could enhance angiogenesis and improve car-diac function after acute myocardial infarction in rats. Mol Cell Biochem, 2010. 339(1-2): 107-18.
49. Zhang D, et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol, 2008. 44(2): 281-92.
50. Zhu X.Y, et al. Transplantation of adipose-derived stem cells overex-pressing hHGF into cardiac tissue. Biochem Biophys Res Commun, 2009. 379(4): 1084-90.
51. Park H.J, Yang F, and Cho S.W. Nonviral delivery of genetic medicine for therapeutic angiogenesis. Adv Drug Deliv Rev, 2012. 64(1): 40-52.
52. Das H, et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One, 2009. 4(10): e7325.
53. Kim S.H, et al. Hypoxia-inducible vascular endothelial growth fac-tor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther, 2011. 19(4): 741-50.
54. Yang F, et al. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci U S A, 2010. 107(8): 3317-22.
55. Mangi A.A, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med, 2003. 9(9): 1195-201.
56. Shujia J, et al. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res, 2008. 77(3): 525-33.
57. Ceradini D.J, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med, 2004. 10(8): 858-64.
58. Dimmeler S. Regulation of bone marrow-derived vascular progenitor cell mobilization and maintenance. Arterioscler Thromb Vasc Biol, 2010. 30(6): 1088-93.
59. Chen F.M, et al. Homing of endogenous stem/progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives. Biomaterials, 2011. 32(12): 3189-209.
60. Petit I, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol, 2002. 3(7): 687-94.
61. Pitchford S.C, et al. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell, 2009. 4(1): 62-72.
62. Orlic D, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A, 2001. 98(18): 10344-9.
63. Zaruba M.M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell, 2009. 4(4): 313-23.